- Home
- CRBU
as 03-28-2025 3:34pm EST
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | BERKELEY |
| Market Cap: | 93.0M | IPO Year: | 2021 |
| Target Price: | $11.80 | AVG Volume (30 days): | 995.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.65 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.88 - $5.15 | Next Earning Date: | 03-10-2025 |
| Revenue: | $9,994,000 | Revenue Growth: | -71.01% |
| Revenue Growth (this year): | 3.5% | Revenue Growth (next year): | 177.84% |
Stock Insider Trading Activity of Caribou Biosciences Inc. (CRBU)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Haurwitz Rachel E. | CRBU | President and CEO | Mar 14 '25 | Buy | $1.02 | 20,000 | $20,400.00 | 3,369,395 | |
| Khan Ruhi Ahmad | CRBU | Chief Business Officer | Feb 20 '25 | Sell | $1.35 | 3,564 | $4,811.40 | 66,936 | |
| Kanner Steven | CRBU | Chief Scientific Officer | Feb 20 '25 | Sell | $1.35 | 3,564 | $4,811.40 | 431,556 | |
| MCCLUNG BARBARA G | CRBU | Chief Legal Officer | Feb 20 '25 | Sell | $1.35 | 3,564 | $4,811.40 | 443,502 | |
| Ryali Sriram | CRBU | Chief Financial Officer | Jan 29 '25 | Buy | $1.42 | 17,360 | $24,651.20 | 17,360 |
Latest Caribou Biosciences Inc. News
CRBU Breaking Stock News: Dive into CRBU Ticker-Specific Updates for Smart Investing
MT Newswires
9 days ago
Truist Removes Price Target on Caribou Biosciences, Keeps Buy Rating; Price Target Was $19
MT Newswires
18 days ago
RBC Cuts Price Target on Caribou Biosciences to $11 From $14, Keeps Outperform, Speculative Risk
Zacks
18 days ago
Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Lags Revenue Estimates
GlobeNewswire
18 days ago
Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Simply Wall St.
a month ago
Caribou Biosciences, Inc. (NASDAQ:CRBU) is a favorite amongst institutional investors who own 62%
GlobeNewswire
a month ago
Caribou Biosciences to Participate in Upcoming Investor Conferences
MT Newswires
3 months ago
Caribou Biosciences Starts Phase 1 Trial for Lupus Drug Candidate
GlobeNewswire
3 months ago
Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025
Compare CRBU vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRBU Caribou Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.